Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Targeting cancer cachexia drivers using antibody-based approaches

Award Number: R01CA281207
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/11/2023
PERIOD OF PERFORMANCE END DATE: 05/31/2029

Group Awards By:

View Award Description

Targeting cancer cachexia drivers using antibody-based approaches - PROJECT SUMMARY Cancer-associated cachexia is a debilitated syndrome that has a dramatic impact on the quality of life and outcome of patients. Cancer cachexia occurs with a remarkably high incidence in pancreatic ductal adenocarcinoma (PDAC) patients. Cancer cachexia is characterized by the progressive depletion of muscle skeletal mass, which often culminates in general organ dysfunction and patient death. Therefore, a deeper understanding of the underlying mechanisms of cancer cachexia would ultimately lead to the identification of innovative therapeutics to improve the management of muscle wasting in cancer patients. Our recent studies have shown that pancreas-specific ablation of the Tgif1 gene in a KrasG12D background led to a dramatic acceleration of PDAC in mice. Quite intriguingly, despite having this severe PDAC phenotype, these mice do not display any prominent sign of cancer cachexia, such as progressive weight loss and decreased muscle mass and function. This contrasts with our previous study using two different mouse models of human PDAC, KPC (KrasG12D and heterozygous deletion of Trp53) and KICLuc (KrasG12D and homozygous deletion of p16Ink4a), which consistently manifest severe cancer cachexia during PDAC progression. These findings hint at the possibility that TGIF1 might function in PDAC cells to initiate events that culminate in muscle cachexia. In efforts to probe this possibility, we generated a new mouse model that allows for conditional overexpression of Tgif1, and found that enforcing TGIF1 expression in the pancreatic epithelium was sufficient to induce muscle cachexia. Subsequent mechanistic experiments revealed an ability of TGIF1 to induce expression of FN14, which functions as a transmembrane receptor in cancer cells to drive inflammation leading to muscle cachexia. Enforced TGIF1 expression also induced the expression of the membrane-bound form of transforming growth factor alpha (TGFa), whose overexpression in the pancreas also drives an inflammatory phenotype similar to what we observed in mice with conditional overexpression of TGIF1. Inspired by these intriguing findings, we created a new bispecific antibody (Bis-14a) to simultaneously neutralize the pro-cachectic activities of FN14 and TGFa. This tremendous progress prompted us to design a variety of innovative genetic and antibody-based pharmacological approaches to provide irrefutable proof-of-principle that targeting FN14 and TGFa downstream of TGIF1 could offer innovative therapeutic strategies to curb cancer cachexia. Overarching specific aims are: Specific Aim 1: Expand role and translational potential of TGIF1 in PDAC-driven muscle cachexia Specific Aim 2) Explore the mechanisms by which TGIF1 facilitates PDAC-driven muscle cachexia Specific Aim 3) Test the therapeutic efficacy of monoclonal and bispecific antibodies targeting FN14 and TGFa signaling in PDAC-mediated muscle cachexia As such, completion of this highly innovative proposal will likely culminate in a paradigm shift in our understanding and treatment of this lethal wasting syndrome.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	WAYNE STATE UNIVERSITY	5700 CASS AVE STE 4900	DETROIT	MI	48202	WAYNE	USA	Cancer Biology Research	001	3	1/20/2026	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$211,518
2026	2025	VIRGINIA COMMONWEALTH UNIVERSITY	910 WEST FRANKLIN ST	RICHMOND	VA	23284	RICHMOND CITY	USA	Cancer Biology Research	000	2	1/20/2026	NON-COMPETING CONTINUATION	-$211,518
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $417,652 )
2025	2025	VIRGINIA COMMONWEALTH UNIVERSITY	910 WEST FRANKLIN ST	RICHMOND	VA	23284	RICHMOND CITY	USA	Cancer Biology Research	001	2	6/5/2025	NON-COMPETING CONTINUATION	$41,765
2025	2025	VIRGINIA COMMONWEALTH UNIVERSITY	910 WEST FRANKLIN ST	RICHMOND	VA	23284	RICHMOND CITY	USA	Cancer Biology Research	000	2	11/19/2024	NON-COMPETING CONTINUATION	$375,887
														Subtotal = $417,652

Issue Date FY: 2024 ( Subtotal = $411,209 )
2024	2024	VIRGINIA COMMONWEALTH UNIVERSITY	910 WEST FRANKLIN ST	RICHMOND	VA	23284	RICHMOND CITY	USA	Cancer Biology Research	000	1	12/11/2023	NEW	$411,209
														Subtotal = $411,209

Grand Total All Awards = $828,861

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting cancer cachexia drivers using antibody-based approaches

Award Number: R01CA281207

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/11/2023

PERIOD OF PERFORMANCE END DATE: 05/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer